Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma.
Molecular therapy. Nucleic acids
View this publicationMolecular therapy. Nucleic acids
View this publicationScience advances
View this publicationMolecular therapy : the journal of the American Society of Gene Therapy
View this publicationNature aging
View this publicationCancer research
View this publicationJournal of clinical medicine
View this publicationJournal of molecular cell biology
View this publicationThe Journal of experimental medicine
View this publicationPublication categories: Top publication
The Journal of experimental medicine
View this publicationFrontiers in immunology
View this publication